Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 993 Neoplasms 852 Carcinoma, Non-Small-Cell Lung 844 Prostatic Neoplasms 528 Neoplasm Metastasis 501 Leukemia, Myeloid, Acute 489 Melanoma 456 Colorectal Neoplasms 447 Multiple Myeloma 441 Lung Neoplasms 421 Pancreatic Neoplasms 353 Recurrence 350 Lymphoma 350 Ovarian Neoplasms 341 Lymphoma, Non-Hodgkin 329 Leukemia 324 Leukemia, Lymphocytic, Chronic, B-Cell 302 Precursor Cell Lymphoblastic Leukemia-Lymphoma 271 Carcinoma, Renal Cell 256 Head and Neck Neoplasms 246 Brain Neoplasms 245 Carcinoma, Hepatocellular 234 Glioblastoma 232 Squamous Cell Carcinoma of Head and Neck 231 Myelodysplastic Syndromes 230 Lymphoma, Large B-Cell, Diffuse 228 Lymphoma, Follicular 219 Colonic Neoplasms 191 Stomach Neoplasms 182 Rectal Neoplasms 175

Interventions

Paclitaxel 1 NVP-BKM120 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Interventional × Non-Small Cell Lunch Cancer × Clear all

NCT01820325 2018-10-11

BASALT-2

Novartis

Phase 1 Terminated

Non-Small Cell Lunch Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡